Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesofiller is a range of injectable dermal fillers developed by mesoestetic Pharma Group, primarily composed of cross-linked hyaluronic acid of non-animal origin. These products are designed for aesthetic dermatological applications, including the temporary correction of facial wrinkles, fine lines, and scars, as well as for skin rehydration. The range includes specific formulations such as Mesofiller Mesotox and Mesofiller AOX (M-AOX-2021), which are intended to provide temporary filling of dermal tissue to correct skin defects while also offering hydration and, in some cases, antioxidant action. The products are administered via intradermal or subcutaneous injection and are characterized as sterile, transparent, and reabsorbable gels produced via bacterial fermentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesofiller.